RhumbLine Advisers’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-48,033
| Closed | -$4.9M | – | 4390 |
|
|
2023
Q2 | $4.9M | Buy |
48,033
+7,625
| +19% | +$777K | 0.01% | 1385 |
|
|
2023
Q1 | $3.67M | Buy |
40,408
+1,456
| +4% | +$132K | ﹤0.01% | 1483 |
|
|
2022
Q4 | $1.48M | Buy |
38,952
+840
| +2% | +$31.9K | ﹤0.01% | 1942 |
|
|
2022
Q3 | $958K | Buy |
38,112
+3,267
| +9% | +$82.1K | ﹤0.01% | 2155 |
|
|
2022
Q2 | $1.06M | Buy |
34,845
+4,864
| +16% | +$148K | ﹤0.01% | 2113 |
|
|
2022
Q1 | $982K | Sell |
29,981
-65
| -0.2% | -$2.13K | ﹤0.01% | 2141 |
|
|
2021
Q4 | $792K | Sell |
30,046
-391
| -1% | -$10.3K | ﹤0.01% | 2311 |
|
|
2021
Q3 | $3.06M | Buy |
30,437
+268
| +0.9% | +$27K | ﹤0.01% | 1651 |
|
|
2021
Q2 | $4.27M | Buy |
30,169
+4,779
| +19% | +$676K | 0.01% | 1506 |
|
|
2021
Q1 | $2.53M | Sell |
25,390
-569
| -2% | -$56.7K | ﹤0.01% | 1798 |
|
|
2020
Q4 | $3.21M | Sell |
25,959
-1
| -0% | -$124 | ﹤0.01% | 1613 |
|
|
2020
Q3 | $2.53M | Sell |
25,960
-1,857
| -7% | -$181K | ﹤0.01% | 1548 |
|
|
2020
Q2 | $4.34M | Sell |
27,817
-10,429
| -27% | -$1.63M | 0.01% | 1299 |
|
|
2020
Q1 | $5.52M | Buy |
38,246
+3,134
| +9% | +$452K | 0.01% | 967 |
|
|
2019
Q4 | $7.18M | Buy |
35,112
+3,880
| +12% | +$793K | 0.01% | 1041 |
|
|
2019
Q3 | $2.51M | Buy |
31,232
+1,729
| +6% | +$139K | ﹤0.01% | 1612 |
|
|
2019
Q2 | $2.78M | Buy |
29,503
+4,501
| +18% | +$425K | 0.01% | 1527 |
|
|
2019
Q1 | $2.14M | Buy |
25,002
+7
| +0% | +$598 | ﹤0.01% | 1668 |
|
|
2018
Q4 | $1.4M | Buy |
24,995
+8,189
| +49% | +$459K | ﹤0.01% | 1851 |
|
|
2018
Q3 | $1.37M | Buy |
16,806
+1,431
| +9% | +$117K | ﹤0.01% | 1853 |
|
|
2018
Q2 | $538K | Buy |
15,375
+5,110
| +50% | +$179K | ﹤0.01% | 2276 |
|
|
2018
Q1 | $211K | Buy |
10,265
+200
| +2% | +$4.11K | ﹤0.01% | 2586 |
|
|
2017
Q4 | $285K | Buy |
10,065
+138
| +1% | +$3.91K | ﹤0.01% | 2492 |
|
|
2017
Q3 | $309K | Buy |
9,927
+350
| +4% | +$10.9K | ﹤0.01% | 2543 |
|
|
2017
Q2 | $303K | Buy |
+9,577
| New | +$303K | ﹤0.01% | 2546 |
|